Literature DB >> 11708989

Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease.

C F Lippa1, M L Schmidt, V M Lee, J Q Trojanowski.   

Abstract

BACKGROUND: Alpha-synuclein is a major component of Lewy bodies (LBs) in Parkinson disease and dementia with LBs and of glial cytoplasmic inclusions in multiple system atrophy. However, epitope mapping for alpha-synuclein is distinctive in different neurodegenerative diseases. The reasons for this are poorly understood but may reflect fundamental differences in disease mechanisms.
OBJECTIVE: To investigate the alpha-synuclein epitope mapping properties of LBs in familial Alzheimer disease. DESIGN AND
SETTING: We compared LBs in familial Alzheimer disease with those in synucleinopathies by probing 6 brains of persons with familial Alzheimer disease using a panel of antibodies to epitopes spanning the alpha-synuclein protein. Results were compared with data from brains of persons with Parkinson disease, dementia with LBs, and multiple system atrophy.
RESULTS: The brains of persons with familial Alzheimer disease showed consistent staining of LBs with all antibodies, similar to Parkinson disease and dementia with LBs but different from alpha-synuclein aggregates that occurred in multiple system atrophy.
CONCLUSIONS: These data suggest that the epitope profiles of alpha-synuclein in LBs are similar, regardless of whether the biological trigger is related to synuclein or a different genetic pathway. These findings support the hypothesis that the mechanism of alpha-synuclein aggregation is the same within cell types but distinctive between cell types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708989     DOI: 10.1001/archneur.58.11.1817

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

1.  Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons.

Authors:  Jozsef Gal; Jing Chen; Yuriko Katsumata; David W Fardo; Wang-Xia Wang; Sergey Artiushin; Douglas Price; Sonya Anderson; Ela Patel; Haining Zhu; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 2.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 3.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

4.  Age at onset in two common neurodegenerative diseases is genetically controlled.

Authors:  Yi-Ju Li; William K Scott; Dale J Hedges; Fengyu Zhang; P Craig Gaskell; Martha A Nance; Ray L Watts; Jean P Hubble; William C Koller; Rajesh Pahwa; Matthew B Stern; Bradley C Hiner; Joseph Jankovic; Fred A Allen; Christopher G Goetz; Frank Mastaglia; Jeffrey M Stajich; Rachel A Gibson; Lefkos T Middleton; Ann M Saunders; Burton L Scott; Gary W Small; Kristin K Nicodemus; Allison D Reed; Donald E Schmechel; Kathleen A Welsh-Bohmer; P Michael Conneally; Allen D Roses; John R Gilbert; Jeffery M Vance; Jonathan L Haines; Margaret A Pericak-Vance
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

5.  αS Oligomers Generated from Interactions with a Polyunsaturated Fatty Acid and a Dopamine Metabolite Differentially Interact with Aβ to Enhance Neurotoxicity.

Authors:  Shailendra Dhakal; Jhinuk Saha; Courtney E Wyant; Vijayaraghavan Rangachari
Journal:  ACS Chem Neurosci       Date:  2021-10-19       Impact factor: 4.418

6.  Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edith Schreiner; Robert Wronski
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 7.  Benefit-risk considerations in the treatment of dementia with Lewy bodies.

Authors:  Margaret M Swanberg; Jeffrey L Cummings
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.